SAVE THE DATE FOR OUR 2019 ANNUAL PUBLIC FORUM ON SEPTEMBER 5, 2019 IN WASHINGTON, DC!
MDIC is the only public-private partnership (PPP) developed to work with government and industry stakeholders in an effort to advance solutions that promote patient access to innovative medical technologies.
MDIC’s Clinical Diagnostics Cancer Genomic Somatic Reference Samples working group seeks public comments on the draft list of prioritized tumor suppressors. The goal of the initiative is to develop reference samples that can be made available to the public to improve the accuracy, reliability and transparency of Next-Generation-Sequencing (NGS) based oncology tests. In addition, the […]
On April 2, 2019, MDIC’s External Evidence Methods (EEM) program hosted an Executive & Fellows meeting with about 70 subject matter experts from FDA, industry, and non-profit organizations to discuss the existing methods and identify gaps for the use of external data. MDIC’s EEM program aims to establish a more predictable pathway for use of external […]
MDIC released a Request for Information (RFI) on March 30, 2019. We are requesting technical information about available and possible approaches for creating a set of human cell lines that include all–or subsets of– specific variants. The variants were drawn from a larger list developed by the MDIC SRS working group and include clinically actionable […]